Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma

AIDS. 2005 Nov 4;19(16):1915-6. doi: 10.1097/01.aids.0000189855.06194.ce.

Abstract

Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Hematologic Diseases / chemically induced
  • Humans
  • Irinotecan
  • Male
  • Middle Aged
  • Sarcoma, Kaposi / complications
  • Sarcoma, Kaposi / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Irinotecan
  • Camptothecin